Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Advanced HER2-Negative Breast Carcinoma”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Large-scale testing (Phase 3)UnknownNCT05673629
What this trial is testing

Utidelone in Combination With AC Versus Docetaxel in Combination With AC for Neoadjuvant Chemotherapy in Patients With HER2-negative Breast Cancer

Who this might be right for
Breast Cancer
Beijing Biostar Pharmaceuticals Co., Ltd. 552
Testing effectiveness (Phase 2)Study completedNCT03481998
What this trial is testing

SHR6390 in Combination With Letrozole or Anastrozole or Fulvestrant in Patients With HR Positive and HER2 Negative Advanced Breast Cancer

Who this might be right for
Advanced Breast Cancer
Jiangsu HengRui Medicine Co., Ltd. 104
Early research (Phase 1)Study completedNCT03471663
What this trial is testing

A First-in-Human Study of D-0502 Alone and in Combination With Palbociclib in Women With Advanced or Metastatic ER-Positive and HER2-Negative Breast Cancer

Who this might be right for
Breast Cancer
InventisBio Co., Ltd 200
Early research (Phase 1)Looking for participantsNCT05187832
What this trial is testing

AND019 in Women With ER Positive HER2 Negative Advanced or Metastatic Breast Cancer

Who this might be right for
Advanced or Metastatic Breast Cancer
Kind Pharmaceuticals LLC 61
Large-scale testing (Phase 3)Looking for participantsNCT05744687
What this trial is testing

Phase II/III Study of SPH4336 Combined With Letrozole vs Placebo Combined With Letrozole in First-line Treatment of Breast Cancer

Who this might be right for
Locally Advanced or Metastatic Breast Cancer
Shanghai Pharmaceuticals Holding Co., Ltd 374
Testing effectiveness (Phase 2)Looking for participantsNCT06201234
What this trial is testing

Evaluating the Addition of Elacestrant (Oral SERD) to Olaparib (PARP-inhibitor) in Patients With Advanced/Metastatic HR+/HER2- Breast Cancer

Who this might be right for
Hormone Receptor Positive HER-2 Negative Breast CancerAdvanced or Metastatic Breast CancerBRCA1 Mutation+1 more
GBG Forschungs GmbH 176
Large-scale testing (Phase 3)Active Not RecruitingNCT04546009
What this trial is testing

A Study Evaluating the Efficacy and Safety of Giredestrant Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Participants With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (persevERA Breast Cancer)

Who this might be right for
Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer
Hoffmann-La Roche 992
Early research (Phase 1)Active Not RecruitingNCT05654532
What this trial is testing

Study of AC699 in Patients With Estrogen Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (ER+/HER2-) Locally Advanced or Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Accutar Biotechnology Inc 100
Testing effectiveness (Phase 2)Looking for participantsNCT05898399
What this trial is testing

Study of ART6043 in Advanced/Metastatic Solid Tumors Patients (POLKA)

Who this might be right for
Advanced Solid TumorMetastatic Solid Tumor
Artios Pharma Ltd 181
Not applicableApproved For MarketingNCT02792725
What this trial is testing

Expanded Access Program to Provide Abemaciclib (LY2835219) for the Treatment of Metastatic Breast Cancer

Who this might be right for
Metastatic Breast Cancer
Eli Lilly and Company
Testing effectiveness (Phase 2)UnknownNCT05953168
What this trial is testing

T-DXd in the First-Line Treatment of Locally Advanced or Metastatic TNBC-LAR HER2-low Patients

Who this might be right for
Triple-Negative Breast Cancer
Fudan University 69
Testing effectiveness (Phase 2)Looking for participantsNCT06908668
What this trial is testing

Evaluate the Efficacy and Safety of Adebrelimab Combined With Chemotherapy With or Without Radiotherapy as Neoadjuvant Treatment for HER2-Negative Locally Advanced Breast Cancer

Who this might be right for
HER2-Negative Locally Advanced Breast Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences 170
Early research (Phase 1)Study completedNCT04132817
What this trial is testing

Multiple Immune and Disease Treatment Combinations in Participants With ER+HER2- Breast Cancer That Has Spread

Who this might be right for
Breast Cancer
Bristol-Myers Squibb 12
Testing effectiveness (Phase 2)Ended earlyNCT02983604
What this trial is testing

GS-5829 in Combination With Fulvestrant or Exemestane in Women With Advanced Estrogen Receptor Positive, HER2 Negative-Breast Cancer

Who this might be right for
Advanced Estrogen Receptor Positive HER2- Breast Cancer
Gilead Sciences 14
Early research (Phase 1)Study completedNCT01281150
What this trial is testing

Veliparib in Combination With Carboplatin and Paclitaxel in Treating Patients With Locally Advanced or Metastatic Solid Tumors

Who this might be right for
Adult Solid NeoplasmEstrogen Receptor NegativeEstrogen Receptor Positive+8 more
National Cancer Institute (NCI) 22
Large-scale testing (Phase 3)Active Not RecruitingNCT05501886
What this trial is testing

Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1)

Who this might be right for
Breast Cancer
Celcuity Inc 701
Large-scale testing (Phase 3)Looking for participantsNCT06954961
What this trial is testing

Evaluate D-0502 in Subjects With ER+ Her2- Locally Advanced or Metastatic Breast Cancer

Who this might be right for
Breast Cancer
InventisBio Co., Ltd 640
Testing effectiveness (Phase 2)Active Not RecruitingNCT03393845
What this trial is testing

Study of Pembrolizumab Plus Fulvestrant in Hormone Receptor Positive, HER-2 Negative Advanced/Metastatic Breast Cancer Patients

Who this might be right for
Breast Cancer
Nancy Chan, MD 47
Testing effectiveness (Phase 2)UnknownNCT03907098
What this trial is testing

Endostar in Combination With Chemotherapy in HER-2 Negative Advanced Breast Cancer

Who this might be right for
Breast Cancer
Zhejiang Cancer Hospital 50
Large-scale testing (Phase 3)Looking for participantsNCT07085767
What this trial is testing

Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer

Who this might be right for
Breast CancerLocally Advanced Breast CancerMetastatic Breast Cancer+2 more
Olema Pharmaceuticals, Inc. 1,000
Next Page